Please wait while the formulary information is being retrieved.
Drug overview for ALPHANATE (antihemophilic factor, human/von willebrand fact,human):
Generic name: ANTIHEMOPHILIC FACTOR, HUMAN/VON WILLEBRAND FACT,HUMAN (FAK-tor VIII/von-WIL-e-brand FAK-tor)
Drug class: Antihemophilic Products
Therapeutic class: Hematological Agents
Antihemophilic factor (human) is a preparation of antihemophilic factor (blood coagulation factor VIII) prepared from pooled human plasma. Antihemophilic factor/von Willebrand factor complex (human) is a preparation of antihemophilic factor and von Willebrand factor prepared from pooled human plasma.
No enhanced Uses information available for this drug.
Generic name: ANTIHEMOPHILIC FACTOR, HUMAN/VON WILLEBRAND FACT,HUMAN (FAK-tor VIII/von-WIL-e-brand FAK-tor)
Drug class: Antihemophilic Products
Therapeutic class: Hematological Agents
Antihemophilic factor (human) is a preparation of antihemophilic factor (blood coagulation factor VIII) prepared from pooled human plasma. Antihemophilic factor/von Willebrand factor complex (human) is a preparation of antihemophilic factor and von Willebrand factor prepared from pooled human plasma.
No enhanced Uses information available for this drug.
DRUG IMAGES
No Image Available
The following indications for ALPHANATE (antihemophilic factor, human/von willebrand fact,human) have been approved by the FDA:
Indications:
Acquired factor VIII deficiency disease
Bleeding episode in acquired factor VIII deficiency disease
Bleeding episode in hemophilia A
Bleeding prevention in von Willebrand disease type 3
Hemophilia A
Prevention of surgery-induced bleed in Von Willebrand's disease
Von Willebrand's disease
Professional Synonyms:
Angiohemophilia
Bleeding prophylaxis in type 3 von Willebrand disease
Congenital factor VIII deficiency disease
Constitutional thrombopathy
Hemorrhaging in hemophilia A
Pseudohemophilia
Vascular hemophilia
Von Willebrand disease
Willebrand-Juergens disease
Indications:
Acquired factor VIII deficiency disease
Bleeding episode in acquired factor VIII deficiency disease
Bleeding episode in hemophilia A
Bleeding prevention in von Willebrand disease type 3
Hemophilia A
Prevention of surgery-induced bleed in Von Willebrand's disease
Von Willebrand's disease
Professional Synonyms:
Angiohemophilia
Bleeding prophylaxis in type 3 von Willebrand disease
Congenital factor VIII deficiency disease
Constitutional thrombopathy
Hemorrhaging in hemophilia A
Pseudohemophilia
Vascular hemophilia
Von Willebrand disease
Willebrand-Juergens disease
The following dosing information is available for ALPHANATE (antihemophilic factor, human/von willebrand fact,human):
Dosage of antihemophilic factor (human) and antihemophilic factor/von Willebrand factor complex (human) is expressed in terms of international units (IU, units); 1 unit of antihemophilic factor is approximately equivalent to the amount of factor VIII in 1 mL of fresh pooled human plasma. In general, administration of 1 unit/kg of these antihemophilic factor preparations will increase the circulating factor VIII level by approximately 2 units/dL (2%).
No enhanced Administration information available for this drug.
No dosing information available.
No generic dosing information available.
The following drug interaction information is available for ALPHANATE (antihemophilic factor, human/von willebrand fact,human):
There are 0 contraindications.
There are 0 severe interactions.
There are 0 moderate interactions.
The following contraindication information is available for ALPHANATE (antihemophilic factor, human/von willebrand fact,human):
Drug contraindication overview.
No enhanced Contraindications information available for this drug.
No enhanced Contraindications information available for this drug.
There are 0 contraindications.
There are 0 severe contraindications.
There are 1 moderate contraindications.
Clinically significant contraindication, where the condition can be managed or treated before the drug may be given safely.
| Moderate List |
|---|
| Thromboembolic disorder |
The following adverse reaction information is available for ALPHANATE (antihemophilic factor, human/von willebrand fact,human):
Adverse reaction overview.
No enhanced Common Adverse Effects information available for this drug.
No enhanced Common Adverse Effects information available for this drug.
There are 20 severe adverse reactions.
| More Frequent | Less Frequent |
|---|---|
| None. |
Allergic dermatitis Anaphylaxis Angioedema Dyspnea Erythema Fibrinogen excess Skin rash Thrombotic disorder Urticaria |
| Rare/Very Rare |
|---|
|
Acute myocardial infarction Cerebrovascular accident Chest tightness Disseminated intravascular coagulation Hemolytic anemia Hypersensitivity drug reaction Hypertension Injection site infection Pulmonary thromboembolism Thromboembolic disorder Wheezing |
There are 24 less severe adverse reactions.
| More Frequent | Less Frequent |
|---|---|
|
Dizziness Fever Headache disorder Injection site sequelae Nausea |
Chest discomfort Chills Drowsy Dyspepsia Flushing Insomnia Lethargy Pruritus of skin Upper respiratory infection Vomiting |
| Rare/Very Rare |
|---|
|
Acute abdominal pain Cough Diarrhea Dysgeusia Fatigue Hypotension Paresthesia Sensation of warmth Tachycardia |
The following precautions are available for ALPHANATE (antihemophilic factor, human/von willebrand fact,human):
No enhanced Pediatric Use information available for this drug.
Contraindicated
Severe Precaution
Management or Monitoring Precaution
Contraindicated
| None |
Severe Precaution
| None |
Management or Monitoring Precaution
| None |
No enhanced Pregnancy information available for this drug.
No enhanced Lactation information available for this drug.
No enhanced Geriatric Use information available for this drug.
The following prioritized warning is available for ALPHANATE (antihemophilic factor, human/von willebrand fact,human):
No warning message for this drug.
No warning message for this drug.
The following icd codes are available for ALPHANATE (antihemophilic factor, human/von willebrand fact,human)'s list of indications:
| Acquired factor VIII deficiency disease | |
| D68.311 | Acquired hemophilia |
| D68.4 | Acquired coagulation factor deficiency |
| Bleeding episode in hemophilia A | |
| D66 | Hereditary factor VIII deficiency |
| Z14.02 | Symptomatic hemophilia A carrier |
| Bleeding in acquired factor VIII deficiency disease | |
| D68.311 | Acquired hemophilia |
| D68.4 | Acquired coagulation factor deficiency |
| Bleeding prevention in von willebrand disease type 3 | |
| D68.03 | Von willebrand disease, type 3 |
| Hemophilia A | |
| D66 | Hereditary factor VIII deficiency |
| Z14.02 | Symptomatic hemophilia A carrier |
| Prevent surg.-induced bleed in von willebrand's disease | |
| D68.0 | Von willebrand disease |
| D68.00 | Von willebrand disease, unspecified |
| D68.01 | Von willebrand disease, type 1 |
| D68.02 | Von willebrand disease, type 2 |
| D68.020 | Von willebrand disease, type 2A |
| D68.021 | Von willebrand disease, type 2B |
| D68.022 | Von willebrand disease, type 2M |
| D68.023 | Von willebrand disease, type 2N |
| D68.029 | Von willebrand disease, type 2, unspecified |
| D68.03 | Von willebrand disease, type 3 |
| D68.04 | Acquired von willebrand disease |
| D68.09 | Other von willebrand disease |
| Von willebrand's disease | |
| D68.0 | Von willebrand disease |
| D68.00 | Von willebrand disease, unspecified |
| D68.01 | Von willebrand disease, type 1 |
| D68.02 | Von willebrand disease, type 2 |
| D68.020 | Von willebrand disease, type 2A |
| D68.021 | Von willebrand disease, type 2B |
| D68.022 | Von willebrand disease, type 2M |
| D68.023 | Von willebrand disease, type 2N |
| D68.029 | Von willebrand disease, type 2, unspecified |
| D68.03 | Von willebrand disease, type 3 |
| D68.04 | Acquired von willebrand disease |
| D68.09 | Other von willebrand disease |
Formulary Reference Tool